Keyphrases
Non-invasive Prenatal Test
100%
Malignancy
76%
Maternal Malignancy
68%
Clinical Follow-up
44%
Pregnant Women
35%
Recurrent Ovarian Cancer
33%
Oral Cyclophosphamide
33%
Bevacizumab
33%
Noninvasive Prenatal Testing
33%
Clinical Management
33%
Pregnancy-associated Cancer
33%
Cell-free DNA Screening
33%
Retrospective Longitudinal Study
33%
Chromosomal Aberrations
11%
Healthcare Professionals
11%
European Countries
11%
Clinical Decision-making
11%
Screening Program
11%
Diagnostic Process
11%
Population-based
11%
Tumor Subtype
6%
Hematological Malignancies
6%
Dutch
6%
Solid Tumors
6%
Platinum Resistance
5%
Systemic Treatment
5%
Platinum Sensitivity
5%
Metronomic Cyclophosphamide
5%
Number of Cycles
5%
Heavily Pretreated
5%
INIS
malignancies
100%
cancer
68%
women
68%
testing
64%
patients
62%
dna
35%
cyclophosphamide
33%
genetics
33%
recommendations
33%
ovaries
33%
management
33%
pregnancy
33%
tumors
22%
screening
12%
chromosomal aberrations
12%
data
10%
solids
10%
platinum
9%
toxicity
9%
decision making
8%
tools
8%
populations
8%
range
6%
therapy
6%
implementation
5%
Medicine and Dentistry
Cancer
100%
Malignant Neoplasm
35%
Cell-Free DNA
35%
Clinical Management
33%
Cell-Free DNA Testing
33%
Cross Sectional Study
33%
Chromosome Aberration
13%
Solid Malignant Neoplasm
12%
Neoplasm
11%
Hematologic Malignancy
10%
Clinical Decision Making
8%
Health Care
8%
Cancer Diagnosis
8%
